# Aditxt, Inc. (ADTX)

> Source: Nexqual · https://nexqual.com/ADTX · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Aditxt, Inc. (ADTX), nexqual.com/ADTX" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–5,833.51 · market cap $998K · PNK

## Key facts
- Last four reported quarters (through Mar 31, 2026): revenue $14K, net income -$53.3M (-372062.4% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $336K; 11 not under a Rule 10b5-1 plan ($336K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 6 Form 4 filings, $335K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -100.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $105K | $934K | $645K | $134K | $3K | $14K |
| Gross profit | $27K | $167K | -$112K | -$493K | $0K | — |
| Operating income | -$41.9M | -$25.5M | -$26.1M | -$27.9M | -$19.6M | -$18.3M |
| Net income | -$46.4M | -$27.6M | -$32.7M | -$40.4M | -$43.1M | -$53.3M |
| EPS (diluted) | -$1183104576000.00 | -$145374048000.00 | -$659949850.08 | -$597980210.94 | -$31153.41 | — |
| Free cash flow | — | -$22.8M | -$19.2M | — | -$25.7M | — |
| Gross margin | 25.8% | 17.9% | -17.3% | -368.3% | 8.4% | — |
| Operating margin | -39925.1% | -2728.9% | -4039.6% | -20796.1% | -612542.2% | -127821.4% |
| Net margin | -44148.9% | -2961.3% | -5068.5% | -30117.9% | -1349028.2% | -372062.4% |
| Revenue growth | — | +789.0% | -30.9% | -79.2% | -97.6% | — |
| Cash + short-term investments | — | $2.8M | $97K | $833K | $3.2M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Mar 31, 2026)
P/S 69.6x · Earnings yield -5344.70%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-23 | Takeover Time 2026 Llc |  | 3,420,439 | $68K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-22 | Hrt Financial Lp |  | 5,120,480 | $92K | 100% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-17 | Drw Securities, Llc |  | 126,772 | $1K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-16 | Hrt Financial Lp |  | 3,132,480 | $41K | 100% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-11 | Bank Of America Corp /de/ |  | 15 | $0K | 23.4% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-11 | Hrt Financial Lp |  | 2,833,463 | $40K | 100% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-09 | Hrt Financial Lp |  | 878,659 | $29K | 45.8% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-09 | Gong Sandie |  | 100,000 | $7K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-05 | Hrt Financial Lp |  | 735,462 | $46K | 100% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-23…2026-04-24 | Hrt Financial Lp |  | 33,215 | $9K | 27.3% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-22 | Hrt Financial Lp |  | 11,982 | $4K | 9% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
6 purchases, $335K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-18 | Hrt Financial Lp |  | 7,340,178 | $95K | 0.01 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-12 | Hrt Financial Lp |  | 4,252,767 | $68K | 0.02 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-11 | Bank Of America Corp /de/ |  | 7 | $0K | 0.01 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-08…2026-06-10 | Hrt Financial Lp |  | 2,148,823 | $84K | 0.04 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-04 | Hrt Financial Lp |  | 843,622 | $64K | 0.08 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-21 | Hrt Financial Lp |  | 72,912 | $24K | 0.33 | Too little history (no open-market trades in 2023 or 2025) |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -100.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -100.0% | -99.9% |
| Volatility (annualized) | 416.4% | 238.2% |
| Max drawdown | -100.0% (Oct 2025→Oct 2026) | -100.0% (Nov 2021→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · AXSM (Axsome Therapeutics, Inc.) USD 145.04 -7.07%

## More
Full page: https://nexqual.com/ADTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2023-12-31) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2023-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |